

Express Mail Label: EL 710 606 310 US  
Docket No. JAB-1669

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Raymond A. Stokbroekx et al.  
Serial No. : 09/998,975 Art Unit: 1624  
Filed : October 19, 2001 Examiner: Truong, Tamthom Ngo  
For : ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-  
THIADIAZOLYL DERIVATIVES

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

AUG 18 2003

Dear Sir:

OFFICE OF PETITIONS

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action

**Express Mail Label: EL 710 606 301 US**  
**Docket No. JAB-1669**

after the filing of a request for continued examination under §1.114,  
no additional fee is required.


- Please charge Deposit Account No. 10-0750/JAB-1669/AGK the fee of \$180.00 as set forth in \$1.17(p).
- Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
  - In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
  - If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
- There are no listed references which are not in the English language.
- The relevance of those listed references which are not in the English language is as follows:
  - Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Express Mail Label: EL 710 606 301 US  
Docket No. JAB-1669

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB-1669/AGK. This form is submitted in triplicate.

Respectfully submitted,

  
Alana G. Kriegsman  
Reg. No. 41,747  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1495  
DATED: June 18, 2003

Express Mail Label: EL 710 606 310 US  
Docket No. JAB-1669

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Raymond A. Stokbroekx et al.  
Serial No. : 09/998,975 Art Unit: 1624  
Filed : October 19, 2001 Examiner: Truong, Tamthom Ngo  
For : ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-  
THIADIAZOLYL DERIVATIVES

Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action

**Express Mail Label: EL 710 606 301 US**  
**Docket No. JAB-1669**

after the filing of a request for continued examination under §1.114,  
no additional fee is required.


- Please charge Deposit Account No. 10-0750/JAB-1669/AGK the fee of \$180.00 as set forth in §1.17(p).
  
- Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
  
- Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
  - In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
  
  - If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
  
  - There are no listed references which are not in the English language.
  
  - The relevance of those listed references which are not in the English language is as follows:
  
  - Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Express Mail Label: EL 710 606 301 US  
Docket No. JAB-1669

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB-1669/AGK. This form is submitted in triplicate.

Respectfully submitted,

  
Alana G. Kriegsman  
Reg. No. 41,747  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1495  
DATED: June 18, 2003

Express Mail Label: EL 710 606 310 US  
Docket No. JAB-1669



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Raymond A. Stokbroekx et al.  
Serial No. : 09/998,975 Art Unit: 1624  
Filed : October 19, 2001 Examiner: Truong, Tamthom Ngo  
For : ANGIOGENESIS INHIBITING 5-SUBSTITUTED-1,2,4-  
THIADIAZOLYL DERIVATIVES

RECEIVED

Commissioner for Patents  
Washington, D.C. 20231

AUG 18 2003

INFORMATION DISCLOSURE STATEMENT

OFFICE OF PETITIONS

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action

TECH CENTER 1600  
JUN 23 2003  
RECEIVED

**Express Mail Label: EL 710 606 301 US  
Docket No. JAB-1669**

after the filing of a request for continued examination under §1.114,  
no additional fee is required.

- Please charge Deposit Account No. 10-0750/JAB-1669/AGK the fee of \$180.00 as set forth in \$1.17(p).
- Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
  - In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
  - If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
- There are no listed references which are not in the English language.
- The relevance of those listed references which are not in the English language is as follows:
- Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

**Express Mail Label: EL 710 606 301 US  
Docket No. JAB-1669**

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB-1669/AGK. This form is submitted in triplicate.

Respectfully submitted,

  
Alana G. Kriegsman  
Alana G. Kriegsman  
Reg. No. 41,747  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1495  
DATED: June 18, 2003

"Express Mail" Label No.  
EL 710 606 301 US

PTO/SB/08A (08-00)

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	
(use as many sheets as necessary)	
Sheet 1 of 1	



Examiner Signature	Date Considered	
-----------------------	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20591.